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Abstract
Certain bioactive food components, including indole-3-carbinol (I3C) and 3,39-diindolylmethane (DIM) from cruciferous
vegetables, have been shown to target cellular pathways regulating carcinogenesis. Previously, our laboratory showed that
dietary I3C is an effective transplacental chemopreventive agent in a dibenzo[def,p]chrysene (DBC)-dependent model of
murine T-cell lymphoblastic lymphoma. The primary objective of the present study was to extend our chemoprevention
studies in mice to an analogous human neoplasm in cell culture. Therefore, we tested the hypothesis that I3C or DIM may
be chemotherapeutic in human T-cell acute lymphoblastic leukemia (T-ALL) cells. Treatment of the T-ALL cell lines CCRF-
CEM, CCRF-HSB2, SUP-T1 and Jurkat with DIM in vitro significantly reduced cell proliferation and viability at concentrations
8- to 25-fold lower than the parent compound I3C. DIM (7.5 mM) arrested CEM and HSB2 cells at the G1 phase of the cell
cycle and 15 mM DIM significantly increased the percentage of apoptotic cells in all T-ALL lines. In CEM cells, DIM reduced
protein expression of cyclin dependent kinases 4 and 6 (CDK4, CDK6) and D-type cyclin 3 (CCND3); DIM also significantly
altered expression of eight transcripts related to human apoptosis (BCL2L10, CD40LG, HRK, TNF, TNFRSF1A, TNFRSF25,
TNFSF8, TRAF4). Similar anticancer effects of DIM were observed in vivo. Dietary exposure to 100 ppm DIM significantly
decreased the rate of growth of human CEM xenografts in immunodeficient SCID mice, reduced final tumor size by 44% and
increased the apoptotic index compared to control-fed mice. Taken together, our results demonstrate a potential for
therapeutic application of DIM in T-ALL.
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Introduction
Acute lymphoblastic leukemia (ALL), the most frequently
diagnosed cancer in children ages 0 to 19 years [1], comprises a
diverse population of malignant lymphoid progenitors undergoing
clonal proliferation at various stages of differentiation [2]. The
American Cancer Society estimates that 6,050 people in the
United States will be diagnosed with ALL in 2012 [3], and
incidence rates of ALL have increased significantly over the past
thirty years [1]. Cases of T-cell origin (T-ALL) comprise 15% of
ALL patients. Prognosis for these patients is poor, because they are
less responsive to combination chemotherapy and are more likely
to relapse than their B-cell counterparts [4].
New strategies in cancer therapy utilize drugs that specifically
target aberrant signaling pathways in order to reduce toxic side
effects, yet such specific therapies are only effective in a small
percentage of this highly heterogeneous disease population. For
example, more than half of T-ALL cases are characterized by a
gain-of-function mutation in the Notch1 receptor, which leads to
constitutive activation of Notch-mediated cell proliferation and
survival [5,6,7]. Therapeutic gamma secretase inhibitors (GSIs)
prevent cleavage of the intracellular Notch (ICN) domain and
subsequent transcriptional activation of Notch target genes
[8,9,10]. Subpopulations of T-ALL patients and cell lines
(including CEM, SUP-T1, and Jurkat cells) are insensitive to
GSI therapy, presumably due to mutations that result in
constitutive ICN expression or additional mutations in genes
downstream [8] such as phosphatase and tensin homolog (PTEN),
a tumor suppressor and negative regulator of the PI3K/AKT/
mTOR signaling pathway [11]. Due to the complexity and
diversity of T-ALL signaling pathways, therapeutic efficacy and
safety may be improved through the use of natural products that
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to systemic or directed chemotherapy [12,13].
Evidence from epidemiological and animal studies shows that
modification of the diet to increase consumption of cruciferous
vegetables is sufficient to reduce cancer risk (reviewed in
[14,15]). Furthermore, maternal consumption of vegetables was
shown to be inversely associated with ALL in a population-based
study [16]. The bioactive food component indole-3-carbinol
(I3C) is produced from the hydrolysis of glucobrassicin, which is
present at high concentrations in cruciferous vegetables, such as
Brussels sprouts, broccoli, cabbage and cauliflower [17]. The
anticancer effects of I3C have been well-documented in various
tumor cell types including colon, breast, and prostate (reviewed
in [18,19]). However, I3C is unstable in acidic environments
such as the stomach and rapidly undergoes self-dimerization and
oligomerization to yield over 15 acid-condensation products
(ACPs) [20]. A major product of this reaction in vitro [21] and in
vivo [22] is 3,39-diindolylmethane (DIM). Because DIM has
greater stability than the parent compound [20,23,24], it is
expected that DIM contributes significantly to the anticancer
effects of dietary I3C and is more effective at an equivalent
molar dose.
Herein, we report for the first time that DIM markedly reduces
the proliferation and survival of four different human T-ALL cell
lines, which were selected to represent the heterogeneity of the
disease. The anticancer effects of DIM were exerted by
modification of critical regulators in the cell cycle pathway leading
to induction of G1 arrest and apoptosis. Subtle differences in
sensitivity within this group of cell lines were observed, although
DIM was more potent than its parent compound I3C in all cases.
Of particular importance was the observation that DIM reduced
growth of human CEM cells in a xenograft model when
supplemented through the diet. Collectively, the data presented
below suggest that DIM could be an effective anticancer agent in
T-ALL cases originating from T cells at different stages of
differentiation and at concentrations that can be reasonably
achieved in vivo in humans and in animal models.
Materials and Methods
Materials
The following chemicals and reagents were purchased from the
indicated suppliers: I3C from Sigma-Aldrich Co. (St. Louis, MO),
Matrigel Matrix from BD Biosciences (Franklin Lakes, NJ) and
ViaCount Flex Reagent from Millipore (Billerica, MA). DNase I
and the NuPAGE system for SDS-PAGE, including 10% and 4–
12% Bis-Tris gels and appropriate electrophoresis and transfer
buffers, were purchased from Invitrogen (Carlsbad, CA).
Antibodies for immunoblotting were obtained from Cell Signal-
ing Technology (Danvers, MA), including b-actin and a-tubulin
primary antibodies and the Cell-Cycle Regulation Antibody
Sampler Kit (contains primary antibodies for CCND3, CDK4,
and CDK6 as well as HRP-linked anti-mouse and anti-rabbit IgG
secondary antibodies). DIM was kindly provided in a bioavailable
formula (BioResponse-DIM, herein referred to as DIM) by
BioResponse, LCC (Boulder, CO), which was certified to contain
30% DIM (wt/wt) by Eurofins-Alpha Laboratories (Petaluma,
CA). This bioavailable form of DIM, rather than the pure
crystalline DIM, has been utilized for many of the preclinical and
clinical studies in the published literature and is the common
form provided in commercial dietary supplements. For these
reasons, we selected the BioResponse formula for the experiments
outlined below. Experimental concentrations reported in this
study were adjusted accordingly (e.g. treatment with 12.3 mg/ml
BioResponse DIM is equivalent to 3.7 mg/ml DIM, or 15 mM
DIM).
Table 1. Human T-ALL cell lines used in this study.
Cell line (abbreviation) CCRF-HSB2 (HSB2) CCRF-CEM (CEM) SUP-T1 Jurkat (JM) Reference
Source (Cat #)* NIH-AIDS (497) ATCC (CCL-119) NIH-AIDS (100) NIH-AIDS (4668)
Age (years)/sex 11/m 3/f 8/m 14/m [25]
Immunophenotypic classification
a Pre-T Pre-T Cortical T Mature T [25]
CD3 (cytoplasmic) 2 +++ [25]
CD3 (surface) 22 2 + [25]
CD4 2 +++ [25]
CD8 22 + 2 [25]
CD1a 22 + 2 [25]
Somatic mutations in T-ALL tumor suppressors
a
CDKN2A(p16) ++ + + [47]
RB1 22 2 2 [47]
TP53 2 +++ [47]
PTEN 2 + 2 + [47]
Oncogene profile (frequency in T-ALL)
NOTCH1 activating mutation (50–60%)
a ++ + + [47,53]
TAL1 expression (25%)
b +++ ++ 2 ++ [53]
STIL-TAL1 fusion
a ++ 22 [53]
LYH1 expression
b ++ + 22 [53]
*ATCC, American Type Tissue Collection; NIH AIDS Research and Reference Reagent Program.
aIndicates presence (+) or absence (2).
bIndicates relative expression (2, +,++,o r+++).
doi:10.1371/journal.pone.0034975.t001
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Cell lines and culture conditions. T-ALL is a
heterogeneous disease resulting from the developmental arrest
and abnormal proliferation of T-cells at different stages of
maturation [25]. Four human T-ALL lines representing this
heterogeneity were selected for this study, including human
CCRF-CEM (CEM) cells, CCRF-HSB2 (HSB2) cells, SUP-T1
cells and Jurkat cells (see Table 1). Cell lines were characterized by
their respective vendors at time of accessioning, and cells were
passaged fewer than 15 times and no longer than 3 months after
acquisition. All cell lines were maintained in phenol red-free
RPMI-1640 medium (Sigma-Aldrich) containing 10% (v/v)
charcoal-stripped, heat-inactivated fetal bovine serum (FBS;
Atlas Biologicals, Fort Collins, CO or Caisson Laboratories,
Logan, UT) in a humidified incubator at 37uC with 5% CO2. The
CEM line was selected for further characterization and study in a
xenograft model based on its classification as an immature
lymphoblastic T-cell population with an immunophenotype
similar to that observed in our murine model of transplacental
carcinogenesis [26] and its demonstrated ability to form solid
tumors in subcutaneous xenograft models [27]. DIM and I3C
were prepared as concentrated stock solutions in DMSO, which
were stored at 280uC protected from light. For in vitro
experiments, cells were seeded 24 hr prior to treatment at
appropriate concentrations for each specific endpoint. On the
day of treatment, dilutions of DIM and I3C were prepared so that
all experimental treatments contained 0.1% DMSO (v/v),
including a vehicle control.
Cell proliferation, viability and apoptosis. T-ALL cells
were treated with 0 up to 60 mM DIM or 0 up to 500 mM I3C for
up to 48 hr. The concentration of viable cells was determined at
each indicated time point by the ViaCount Assay (Millipore,
Billerica, MA) as recommended by the manufacturer using either
the Guava Personal Cell Analyzer (Guava Technologies, Inc.,
Hayward, CA) or the Accuri C6 flow cytometer (BD Accuri
Cytometers, Inc., Ann Arbor, MI); assay performance was
comparable on both instruments. Raw data were compared to
the time-zero control for cell proliferation and the time-matched
control for viability. Concentration values for 50% inhibition
(IC50) of T-ALL cell proliferation and viability by I3C and DIM
were calculated by non-linear regression using a sigmoidal dose-
response with variable slope (Prism 5, GraphPad Software, La
Jolla, CA).
Cell-cycle analysis. T-ALL cells were treated with 0 to
15 mM DIM for up to 48 hr, rinsed in cold PBS, fixed in ice cold
70% EtOH, and stored at least overnight at 220uC. On the day of
analysis, cells were washed with PBS and incubated for 30 min in
the dark in staining solution (25 mg/ml propidium iodide, 0.1%
Figure 1. I3C and DIM reduce proliferation and viability of CEM cells. Cells were treated with 0 (%), 1.9 (m), 3.8 (,), 7.5 (X), 15 (#), or 30
(&) mM DIM (panels A,C) or 0 (%), 15.6 (m), 31.3 (,), 62.5 (X), 125 (#), 250 (&), or 500 (e) mM I3C (panels B,D) for 24 or 48 hr, then stained with
ViaCount reagent for analysis of viable cell concentration and percent viability. Values are the mean fold change in cell proliferation (panels A, B) or
percent viability (panels C, D) 6 SEM (n=3 independent experiments) normalized to control cells at 0 hr. **, p,0.01 and ***, p,0.001, as determined
by two-way ANOVA with Bonferroni post-hoc test comparisons for significant effects of DIM treatments at each time point compared to time-
matched vehicle control (0.1% DMSO).
doi:10.1371/journal.pone.0034975.g001
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cytometry was used to determine cellular DNA distribution
using the Guava PCA or Accuri C6 instruments and the
number of cells in each cycle were analyzed using MultiCycle
software (Phoenix Flow System, San Diego, CA) or FlowJo
Cytometry Analysis Software (Ashland, OR).
Immunoblotting. Cells were treated with 0 to 15 mM DIM
for 12 or 24 hr or with 0 to 500 mM I3C for 24 hr, then lysed in IP
lysis buffer (20 mM Tris, 150 mM NaCl, 1 mM EDTA, 1 mM
EGTA, 1% (v/v) Triton X-100, 2.5 mM Na4P2O7?10H2O, 1 mM
C3H9O6P, 1 mM Na3VO4,1mg/ml leupeptin and 0.5% protease
inhibitor cocktail III (EMD Chemicals, Gibbstown, NJ)). Protein
concentration was determined using the Coomasie Plus Assay
(Thermo Scientific, Rockford, IL) and an equal amount of protein
for each sample was separated by SDS-page electrophoresis and
transferred to nitrocellulose membranes. Membranes were
blocked for 1 hr in 5% non-fat milk or BSA prior to overnight
incubation at 4uC with primary antibodies for CCND3, CDK4, or
CDK6 (all 1:1000 dilution). Membranes were subsequently
incubated with the appropriate HRP-conjugated secondary
antibody for 1 hr. Immunoreactive proteins were visualized
using an Alpha Innotech Imaging Station (Cell Biosciences,
Santa Clara, CA) and the Western Lightning ECL reagent (Perkin
Elmer, Waltham, MA). Protein bands of interest were measured
by densitometry using FluorChem 8800 software (Cell Biosciences,
Santa Clara, CA). Membranes were stripped using Restore
Western Blot Stripping Buffer (Thermo Scientific) and tested for
removal of antibodies before re-probing with b-actin or a-tubulin.
Changes in protein expression, normalized to b-actin or a-tubulin,
were calculated as the mean difference in percentage compared to
time-matched vehicle controls (0.1% DMSO), which were
assigned a value of 100%.
TUNEL analysis in vitro. The terminal deoxynucleotidyl
transferase dUTP nick end labeling method (TUNEL) was applied
to CEM treated with 0–15 mM DIM for 48 hr. The In Situ Cell
Death Detection kit with Fluorescein (Roche Applied Science,
Indianapolis, IN) was used to label DNA strand breaks and the
Guava Express Plus program was used to sort and quantify the
amount of TdT incorporation. Detailed methods, including
sample preparation and fluorescent microscopy, are provided in
File S1. The apoptotic index (AI) was calculated from the flow
cytometry results as follows: AI=(number of TUNEL-positive
cells/total number of cells)6100.
Quantitative PCR for apoptosis pathway. Total RNA was
extracted using TRIZOL reagent (Sigma-Aldrich) as
recommended by the manufacturer from triplicate samples of
CEM cells treated with 7.5 mM DIM for 4 or 24 hr. cDNA
synthesis was performed using 2 mg RNA per sample with the RT
2
First Strand Synthesis Kit (SABiosciences, Frederick, MD);
quantitative PCR analysis for 84 genes related to human
apoptosis was performed using the RT
2 Profiler PCR Array
System (SABiosciences) with the iCYCLER iQ5 Real-Time PCR
System (Bio-Rad, Hercules, CA). Relative gene expression was
calculated using the DDCt method [28] with the housekeeping
genes B2M and GAPDH selected for normalization. Transcripts
were considered absent if Ct.35 and were removed from analysis.
In vivo xenograft study with human CEM cells
Animal care and diet preparation. All protocols for the
handling and treatment of mice were reviewed and approved by
the Oregon State University Institutional Animal Care and Use
Committee (Animal Care and Use Protocol #3837). Male
NOD.CB17-Prkdc
scid/SzJ (SCID) mice were purchased from
Jackson Laboratories (Bar Harbor, ME) at 7 weeks of age and
housed at the Laboratory Animal Resource Center at Oregon
State University under controlled conditions of 2061uC and
50610% humidity with a 12:12 hr light/dark cycle in micro-
isolator cages (Super Mouse750
TM Micro-Isolator
TM, Life
Products, Seaford, DE) with CareFRESH bedding. Mice were
acclimated for one-week prior to any experimental procedures.
Experimental diets were prepared by incorporating 500 or
2000 mg I3C, or 350 mg BioResponse-DIM (contains 100 mg
DIM) per kg of powdered AIN93G diet (Research Diets, New
Brunswick, NJ). All prepared diets were c-irradiated (2.5 mRads)
and stored at 220uC, protected from light throughout the course
of the study.
CEM cell xenograft study. Detailed methods for the
xenograft study are provided in File S1. Briefly, CEM cells were
freshly collected, prepared in a 1:1 (v/v) solution of medium/
Matrigel, and engrafted subcutaneously (10
7 cells/site) into SCID
mice. Mice were fed diets containing 500 ppm I3C, 2000 ppm
I3C, or 100 ppm DIM (350 ppm BioResponse-DIM) ad libitum for
one-week prior to engraftment and throughout the course of the
study. Xenograft measurements were conducted every third day
with digital calipers, and tumor volume was estimated using the
equation for an ellipsoid (L6W
26p/6).
TUNEL analysis of human CEM cell xenografts. Detailed
methods for staining and analysis of xenograft tissues by TUNEL
for detection of apoptosis are provided in File S1. Briefly, serial
sections of xenografts were stained using the In Situ Cell Death
Detection kit, POD (Roche Applied Science) with few
modifications from the manufacturer’s protocol. The apoptotic-
index (AI) was calculated as follows: AI=(manual count TUNEL
positive/auto count negative)6100.
Figure 2. Comparison of I3C and DIM in multiple human T-ALL cell lines. Human CEM, HSB2, SUP-T1 and Jurkat cells were treated for 48 hr
with I3C (15.6 up to 500 mM) or DIM (1.9 up to 60 mM), then stained with ViaCount reagent for analysis of cell concentration and percent viability.
Values are the mean level of cell proliferation (panels A–D) or the mean percent viable cells (panels E–F) 6 SEM (n=3 independent experiments),
normalized to the time-matched vehicle control (0.1% DMSO). Non-linear regression analysis (four parameter, variable slope) was performed
(GraphPad Prism) to generate the concentration-response curve for each chemical in each cell line, from which IC50 values were obtained (see
Table 2).
doi:10.1371/journal.pone.0034975.g002
Table 2. Inhibition of T-ALL cell growth by DIM and I3C.
IC50 (mM) for DIM IC50 (mM) for I3C
Cell line Proliferation Viability Proliferation Viability
CEM 15 27 122 223
HSB2 8 7 86 83
SUP-T1 13 14 262 284
Jurkat 9 15 228 222
Note: Non-linear regression analyses (four parameters, variable slope) were
performed using data generated from each DIM and I3C concentration-
response curve generated for each of the four cell lines tested (GraphPad Prism
v5.0, San Diego, CA). IC50 values are the concentrations of DIM or I3C required
to inhibit cell proliferation or viability by 50% compared to the vehicle control
(0.1% DMSO).
doi:10.1371/journal.pone.0034975.t002
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70% EtOH and stained with propidium iodide. DNA content distribution was analyzed by Guava PCA or Accuri C6 flow cytometry. (A–B)
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GraphPad Prism 5 software (La Jolla, CA) was used for all
statistical analyses. One or two-way ANOVA were performed as
appropriate for the number of experimental factors being
examined. Statistical significance was inferred when p,0.05 and
was denoted in each figure as follows: *, p,0.05; **, p,0.01, and
***, p,0.001. Non-linear regression analyses were performed
using the equation for exponential growth to determine the impact
of experimental diet on the doubling time (DT) of CEM
xenografts. DT was calculated as follows: DT=[(To2Ti)ln2]/
ln(Vo/Vi) where Ti and To represent the initial and final time
points and Vi and Vo represent initial and final tumor volumes. A
significant effect of DIM on gene expression was inferred when the
relative fold change was greater than 1.5-fold (log2 R,20.58 or
.0.58) with a p-value,0.05 (Student’s t-test) compared to time-
matched controls.
Results
Impact of DIM treatment CEM cells in vitro
DIM and I3C inhibit proliferation of CEM cells. To
determine the impact of DIM and I3C on growth of a
representative human T-ALL cell line, a time-course study was
performed over a range of concentrations using CEM cells. DIM
and I3C blocked the proliferation of CEM cells in a time- and
concentration-dependent manner (Fig. 1A–B). Treatment with the
highest concentrations of DIM or I3C significantly reduced CEM
cell viability by up to 58 or 82%, respectively (Fig. 1C–D).
Significant inhibition of proliferation and a decrease in viability
was observed after 24 hr treatment with DIM or I3C, with the
greatest response observed by 48 hr. However, I3C was
substantially less effective, as much greater concentrations
(.62.5 mM) were required to significantly reduce CEM cell
growth or decrease viability compared to DIM (.7.5 mM).
Comparison of efficacy of DIM and I3C in multiple T-ALL
cell lines. Concentration-response experiments were performed
in four different T-ALL cell lines to determine whether DIM and
I3C are similarly effective in reducing growth of T-ALL cells
derived from T-cells at different stages of differentiation. In all cell
types, in vitro treatment with DIM for 48 hr markedly reduced cell
proliferation (IC50 values of 8 to 15 mM) and cell viability (IC50
values of 7 to 27 mM), whereas I3C was much less effective
(proliferation IC50 values of 86 to 262 mM; viability IC50 values of
83 to 284 mM) (Fig. 2; Table 2). HSB2 cells were the most sensitive
to inhibition of cell growth by DIM and I3C.
DIM induces cell cycle arrest in CEM and HSB2
cells. The marked suppression of proliferation by DIM
prompted us to evaluate cellular DNA content by flow
cytometry in each of the four T-ALL cell lines. Treatment of
CEM or HSB2 cells with 7.5 or 15 mM DIM for 48 hr resulted in
a significant G1 cell cycle arrest, with substantially fewer cells
progressing to the G2/M phase (Fig. 3). Shorter duration DIM
treatment (6 and 12 hr) in CEM cells also caused a significant G1
arrest (data not shown). On the other hand, DIM treatment did
not significantly alter cell cycle progression in either SUP-T1 or
Jurkat cells (Fig. 3). Additionally, at the higher concentrations of
DIM tested, a sub-G1 peak was observed in the raw histogram
data (for example in CEM cells approximately 10% at 7.5 mM,
and about 14% at 15 mM; data not shown) indicating an
increasing population of apoptotic cells.
Next, we measured the expression of key regulatory proteins of
cell cycle progression by immunoassay in CEM cells. DIM
suppressed expression of key cell cycle regulatory proteins in vitro,a
finding that is consistent with DIM-induced G1 growth arrest
(Fig. 4). Treatment with DIM for 12 or 24 hr decreased expression
of CCND3 and CDK4 proteins in a concentration-dependent
manner (i.e., 38% and 56% decrease after treatment with 15 mM
DIM for 24 hr, respectively), whereas a trend for decreasing
CDK6 expression was evident (up to 48% decrease after 15 mM
DIM for 24 hr). I3C also decreased expression of CCND3, CDK6
and CDK4 at 24 hr (data not shown), albeit at supra-physiological
concentrations (.100 mM) that have been shown to be cytotoxic
in healthy peripheral blood mononuclear cells [29].
DIM induces apoptosis in T-ALL cells. Two methods for
assessing the impact of DIM on apoptosis were used in this study.
First, the portion of apoptotic cells following treatment with DIM
for 48 hr was determined by the ViaCount assay. In all four T-
ALL cell types, treatment with 15 mM DIM caused a significant
increase in the percentage of apoptotic cells (Fig. 5), although the
sensitivity to DIM varied with cell type. For example, HSB2 cells
were the most sensitive to DIM-induced apoptosis (significant
increase in apoptosis at DIM concentrations .7.5 mM up to 52%),
whereas apoptosis was only modestly increased in Jurkat cells (10%
apoptosis at 15 mM DIM).
Next, the extent of DNA strand breaks in vitro was analyzed
using the TUNEL method and a commercially available kit (In Situ
Cell Death Detection Kit, Roche Applied Science) in the CEM
cell line only. Marked incorporation of fluorescein-dUTP was
evident by fluorescence microscopy (Fig. 6A). Fixed and stained
samples were applied to a benchtop flow cytometer (Guava PCA)
for quantitative analysis of results. This approach identified
populations of both low and high TdT incorporation by
fluorescence intensity, reflective of low and high cellular levels of
apoptosis (Fig. 6B). For all concentrations of DIM tested, the low
intensity apoptotic index increased in a concentration-dependent
manner relative to controls, with the percentage of CEM cells
undergoing low levels of apoptosis ranging from 2 to 13%. At
higher concentrations ($7.5 mM) of DIM, an increase in the
number of cells with a high level of apoptotic response was also
observed. Apoptosis was detected in 22% of the cell population at
the highest concentration of DIM tested.
DIM alters expression of genes that regulate the
apoptosis pathway. We determined the effects of DIM on
expression of gene targets relevant for regulation of apoptosis in
humancells.Fold changevaluesandresults ofthe statisticalanalyses
for all gene targets on the apoptosis PCR pathway array are
provided in Table S1. In vitro exposure to 7.5 mM DIM for 4 hr
significantly altered the expression level of eight genes more than
1.5-fold (p,0.05) with respect to the time-matched controls
(Table 3). This set of genes accounted for 9.5% of transcripts
queried by the quantitative PCR apoptosis pathway array. Among
those transcripts, BCL2L10, CD40LG, HRK, TNFRSR1A and
TNFSF8 were significantly induced, while only TNF was repressed.
Following 24 hr of DIM exposure, expression levels of CD40LG
and HRK remained elevated, while TNFRSF25 and TRAF4 were
significantly repressed (,21.5-fold, p,0.05) (Table 3).
Representative histograms are shown for control and 15 mM DIM treatments at 48 hr in human CEM cells. (C–D) Distributions of CEM, HSB2, SUP-T1 or
Jurkat cells in G1 (black), S (white), and G2 (grey) phases of cell-cycle progression at 48 hr (n=3 to 5 independent experiments). *, p,0.05; **, p,0.01
or *** p,0.001 for G1 arrest compared to the vehicle control (0.1% DMSO) as determined by one-way RM ANOVA (matching by experiment day) with
Dunnett’s multiple comparisons post-hoc test.
doi:10.1371/journal.pone.0034975.g003
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DIM and I3C inhibit growth of CEM xenografts in
vivo. Another key objective of this study was to determine
whether dietary DIM or I3C reduced the growth of human CEM
cells in vivo using a SCID mouse xenograft model. The rate of body
weight gain or average final body weight was not significantly
affected by any of the dietary treatments (Fig. S1). On average,
animals in the DIM group consumed about 0.4 mg DIM/day,
based on per cage diet consumption data (Fig. S1B). The rate of
successful CEM engraftment in this study was high (57/59
animals), with solid nodules palpable within one week
(approximately 250 mm
3). In this study, short-term (1 week pre-
engraftment+28 days post-engraftment; 35 days total) dietary
treatment with 100 ppm DIM, 500 ppm I3C or 2000 ppm I3C
did not significantly affect average body weight or rate of body
weight gain (Fig. S1A). Animals fed 500 ppm I3C apparently
consumed less food on a daily basis compared to the other diet
groups (Fig. S1B.); one animal was removed from this group due to
an unrelated health problem. Tumor volume in control-fed
animals increased by about 600%, with an average doubling
Figure 4. DIM reduces expression of cell-cycle regulatory
proteins. Following either 12 hr (gray bars) or 24 hr (black bars)
treatment with increasing concentrations of DIM, CEM cells were
harvested and protein immunoassays were performed for detection of
CCND3, CDK4 and CDK6 proteins (three replicate experiments
performed). (A) A representative immunoblot is shown for each protein
assay. (B) Values shown are average protein expression 6 SEM
normalized to b-actin, expressed as a percentage difference from
time-matched vehicle controls (0.1% DMSO), which were assigned a
value of 100%. *, p,0.05 or **, p,0.01 compared to 0 mM DIM (vehicle
control) as determined by one-way ANOVA with Dunnett’s post-hoc
test for multiple comparisons; overall ANOVA p-values within each time
group are indicated in each panel. In some cases where the p-value for
the ANOVA was not ,0.05, a significant linear trend was evident, as
indicated by trend p-values in the figure. Finally, a Student’s t-test
(###, p,0.001) was performed to compare 15 mM DIM to vehicle
control for CCND3 expression at 24 hr because high variability observed
at the 3.8 mM concentration confounded the ANOVA post-hoc results
(overall effect of DIM was significant).
doi:10.1371/journal.pone.0034975.g004
Figure 5. DIM induces apoptosis in human T-ALL cells. CEM,
HSB2, SUP-T1 and Jurkat cells were treated with 3.8 to 15 mM DIM for
48 hr. Values are the proportion of apoptotic cells as determined using
the ViaCount assay + SEM (n=3 to 4 independent experiments). *,
p,0.05; **, p,0.01 or *** p,0.001 for compared to the vehicle control
(0 mM DIM, 0.1% DMSO) as determined by one-way RM ANOVA
(matching by experiment day) with Dunnett’s multiple comparisons
post-hoc test.
doi:10.1371/journal.pone.0034975.g005
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reduced growth of CEM xenografts (p=0.041, two-way RM
ANOVA), and a significant effect of dietary DIM on CEM nodule
size was detected by day 25 (p,0.05, Bonferroni’s post-hoc tests
compared to control) (Fig. 7A). At the conclusion of the study, the
final average tumor size in DIM-treated animals was substantially
and significantly reduced (44% decrease in volume) compared to
control animals. Moreover, the rate of growth of CEM cell
xenografts in animals fed 100 ppm DIM was significantly slower
with a DT of 10.2 days (Table 4) compared to 6.4 days for control
fed animals (p,0.001 by one-way ANOVA). I3C was less effective
at reducing xenograft growth; 500 and 2000 ppm diet
concentrations decreased tumor volume by 25% or 27% by day
28, respectively, although these levels of effect were not statistically
significant (500 ppm I3C, p=0.356; 2000 ppm I3C, p=0.271, by
two-way RM ANOVA) (Fig. 7B). However, tumor growth rate
was significantly reduced by 2000 ppm I3C, with a calculated
doubling time of 8.5 days (p=0.006) (Table 4).
Dietary DIM induces apoptosis in CEM xenografts.
Because high rates of apoptosis were detected in CEM cells
exposed to DIM in vitro, apoptosis was also assessed in CEM
xenografts following dietary exposure to 100 ppm DIM, 500 ppm
I3C, and 2000 ppm I3C (Fig. 8A). Dietary DIM resulted in a
significant (p,0.001), two-fold increase in the number of TUNEL-
positive cells in mice fed DIM (3.460.5%) compared to control
mice (1.760.2%). Alternatively, AI values for xenograft sections
from mice exposed to 500 or 2000 ppm I3C were not significantly
different from control (Fig. 8B).
Discussion
We provide evidence for the first time that DIM significantly
impairs the growth of human T-ALL cells in vitro and in vivo.
Moreover, we show that DIM blocks growth of T-ALL cell types
that represent the spectrum of T-cell differentiation arrest
occurring within this disease, ranging from least differentiated to
nearly mature (HSB2.CEM.SUP-T1.Jurkat). All four T-ALL
cell types studied responded to DIM treatment in a dose-
dependent manner, as shown by inhibition of cell proliferation
and viability and increased levels of apoptosis; in addition, a G1
Figure 6. DIM induces apoptosis in CEM cells as detected by TUNEL. The In situ cell death detection kit (TUNEL) was applied to fixed CEM
cells treated with 0 to 15 mM DIM for 48 hr. (A) Fluorescence images of control (0 mM) and DIM-treated (15 mM) cells were taken at 206magnification
following TUNEL labeling in mounting medium with DAPI. (B) Flow cytometry was used to identify and quantify cells with no, low (open bar) or high
(solid bar) intensity staining. **, p,0.01 or ***, p,0.001 as determined by one-way ANOVA with Dunnett’s post-hoc test comparisons for significant
effects of DIM treatments within each intensity category as compared to vehicle control (0 mM DIM, 0.1% DMSO).
doi:10.1371/journal.pone.0034975.g006
Table 3. DIM-induced changes in expression of select apoptosis-related genes in CEM cells. *
Log2 R( p-value)
{
Unigene Symbol Description 4 hours 24 hours
Hs.283672 BCL2L10 BCL2-like 10 (apoptosis facilitator) 1.05 (0.459) 0.63 (0.023)
Hs.592244 CD40LG CD40 ligand 0.75 (0.019) 0.62 (0.043)
Hs.87247 HRK Harakiri, BCL2 interacting protein (contains only BH3 domain) 0.88 (0.014) 1.35 (0.004)
Hs.241570 TNF Tumor necrosis factor (TNF superfamily, member 2) 20.63 (0.016) 20.39 (0.026)
Hs.279594 TNFRSF1A Tumor necrosis factor receptor superfamily, member 1A 1.22 (0.002) 20.46 (0.331)
Hs.462529 TNFRSF25 Tumor necrosis factor receptor superfamily, member 25 nd
{ 21.15 (0.015)
Hs.654445 TNFSF8 Tumor necrosis factor (ligand) superfamily, member 8 0.90 (0.026) 0.34 (0.009)
Hs.8375 TRAF4 TNF receptor-associated factor 4 nd 20.59 (0.017)
*A complete list of DIM-induced changes in gene expression, including all genes on the RT
2 Profiler Apoptosis array, is provided in Table S1.
{Log2 fold change (R) values are highlighted in bold if level of change is .1.5-fold (Log2 R,20.58 or .0.58) compared to vehicle (0.1% DMSO) control. p-values were
determined by a Student’s t-test assuming equal variances.
{nd, not detected by RT
2 PCR profiler array at this time point (Ct.35).
doi:10.1371/journal.pone.0034975.t003
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represent early (pre-T) differentiated cells. In this study, we also
show that the I3C derivative, DIM, was far more potent than its
precursor and exhibited therapeutic effects on a variety of highly
aggressive juvenile T-ALL cell lines, including Jurkat and CEM, at
physiological concentrations. Others have reported that I3C
suppressed NFkB stimulation by TNF and downstream gene
products, including CCND1, BCL-2 and TRAF1, in myeloid and
leukemia (Jurkat) cells [30], but I3C was not capable of blocking
the growth of T-cell lines that were not infected with human T-cell
leukemia virus type-1 (MOLT-4, Jurkat and CCRF-CEM) [29].
The SCID mouse model supports the solid growth of
subcutaneously injected human acute leukemia blast cells in a
manner that is easily measurable and exhibits a dissemination
pattern analogous to the human disease [31,32]. We supplemented
this pre-clinical model with dietary indoles to determine the extent
of xenograft growth suppression following absorption, metabolism
and disposition to the grafted cells. This study is the first to employ
continuous exposure of I3C or DIM through the diet, as opposed
to bolus administration via gavage or injection, with a human cell
xenograft model in SCID mice. In the present study, growth of
human CEM cell xenografts in mice consuming DIM (approxi-
mately 0.4 mg/day) was only about half that of the control
animals, an observation that is comparable to other studies with
breast cancer cell xenografts that employed even greater amounts
of DIM or more direct routes of exposure. For example, oral
gavage of about 1 mg DIM/day (3.5 mg BioResponse-DIM/day)
decreased growth of MDA-MB-231 xenografted cells by approx-
imately 30% after 3 weeks of exposure [33] whereas daily 5 mg/kg
s.c. injections of DIM at the site of MCF-7 xenografts reduced
tumor volume by about 45% [34].
We selected a dietary concentration of 2000 ppm I3C level
based on the apparent anticancer effects at this level observed in
our previous studies [26,35]. The likely proportion of this I3C diet
Figure 7. DIM and I3C suppress CEM cell xenograft growth. Male NOD.CB17-Prkdc
scid/SzJ mice were engrafted with CEM cells as described in
Materials and Methods and fed control diet (CTRL), 100 ppm DIM (panel A) or 500 or 2000 ppm I3C (panel B) for 28 days. Growth of xenografts was
assessed every third day and compared to nodule volumes in control-fed animals. *, p,0.05 or **, p,0.01 as determined by two-way repeated
measures ANOVA with Bonferroni post-hoc tests to evaluate the effects of diet on tumor growth at each time point compared to the time-matched
control. p-values for overall effect of each treatment on tumor growth compared to control are: 100 ppm DIM, p=0.041; 500 ppm I3C, p=0.356; and
2000 ppm I3C, p=0.271.
doi:10.1371/journal.pone.0034975.g007








Control 13606222 6.43 (5.22–8.35)
100 ppm DIM (350 ppm BR-DIM) 7616153 ** 10.2 (7.51–15.9)
###
500 ppm I3C 10306318 7.57 (5.43–12.5)
2000 ppm I3C 9946191 8.45 (6.47–12.2)
##
Note:
**, p,0.01 as determined by two-way ANOVA with Dunnett’s post-hoc test comparisons for significant effect of experimental diet compared to the time-matched
control (day 28 values for tumor volume are shown).
##, p,0.01 or
###, p,0.001 as determined by one-way ANOVA with Dunnett’s post-hoc test comparisons for significant effects of experimental diets compared to control.
{Tumor growth rates were modeled by non-linear regression analyses using the exponential growth equation with least-squares fit (Prism 5). Average doubling time
(DT) values are shown and were calculated as follows: DT=[(To2Ti)6ln2]/ln(Vo/Vi) where Ti and To represent the initial and final time points and Vi and Vo represent
initial and final tumor volumes. p-values (extra sum of squares F test) are reported for comparison of calculated growth curves for indicated treatments compared to
control diet.
doi:10.1371/journal.pone.0034975.t004
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to a diet concentration of 350 ppm DIM, based on a 2:1 molar
ratio and assuming a 20% conversion rate [20,23]. The
BioResponse-DIM formulation is a commercially available dietary
supplement, sold for human consumption, that is also used in
animal studies and clinical trials; thus, 350 ppm BioResponse-
DIM (100 ppm DIM) was selected in anticipation of comparable
bioactivity to the 2000 ppm I3C treatment [23]. Pharmacokinetic
studies in mice comparing this formulated DIM to crystalline DIM
demonstrate a 50% improvement in adsorption [23]. This
difference in bioavailability, along with the rapid elimination of
I3C and formation of additional bioactive I3C derivatives, may
account for the reduced efficacy of 2000 ppm I3C in vivo
compared to 100 ppm DIM.
DIM was also significantly more potent than I3C in vitro based
on the relative IC50 values for inhibition of cell proliferation and
viability across all cell lines tested. Moreover, the anti-proliferative
effect of I3C was delayed compared to DIM, suggesting that
conversion of I3C to DIM and other ACPs in the culture media
may contribute to the physiological effects of I3C. A recent report
by Bradlow and Zeligs [36] showed that addition of 100 mM I3C
to culture media at a neutral pH resulted in concentrations of DIM
of about 25 mM within 24 hours. However, because the degree of
difference in potency of DIM and I3C varied across the four T-
ALL cell lines tested and by the endpoint examined (viability,
proliferation) in this study, the apparent lower potency of I3C
compared to DIM cannot be fully explained by conversion of I3C
to DIM in the culture media.
Other plausible explanations exist for the distinctive responses
to DIM observed in the four T-ALL cell lines studied, which are
characterized by different lineages of T-cell differentiation (pre-T,
cortical-T and mature-T), as well as different ages and genders of
the source patients (Table 1). Gene deletions and mutations as well
as epigenetic mechanisms of gene dysregulation are commonly
implicated in the oncogenesis of T-cells and in therapeutic
outcome [37,38,39]. Common leukemic signature genes include
those involved in normal T-cell receptor signaling and T-cell
differentiation such as NOTCH1, NOTCH3, HOX11, TAL1, LYL1
and LMO1 [5,37]. A selection of these therapeutically relevant
targets and their status in HSB2, CEM, SUP-T1 and Jurkat cells
are listed in Table 1.
Although beyond the scope of this study, the different
combinations of these aberrations across the cell lines tested are
likely to play a role in the therapeutic effect of DIM. The variable
responses to both targeted and conventional chemotherapeutic
drugs that have been previously observed in T-ALL cells are likely
a consequence of the respective mutations harbored by the cell
lines (e.g., [11,40]). Thus, the observation that DIM had variable
potency for blocking growth of T-ALL cells (though effective in all
four cell lines tested) is not necessarily unexpected given the
apparent variability in response of T-ALL cells to drug therapies.
Treatment of CEM and HSB cells with DIM caused a blockade
of cell-cycle progression at the G1 phase checkpoint, although this
effect was not observed in more differentiated T-ALL cell lines
(SUP-T1 or Jurkat); DIM (and I3C) also suppressed expression of
CCND3, CDK4 and CDK6 cell cycle regulatory proteins in CEM
cells. Early progression of the eukaryotic cell cycle is positively
regulated by the coupling of D-type cyclins with the highly
homologous CDK4 or CDK6 proteins and negatively regulated by
cyclin dependent kinase inhibitors and phosphatases [41]. I3C and
DIM inhibit proliferation and cell cycle progression of various
tumor cells, including breast [42], prostate [43] and colon [44], via
down-regulation of cyclins and cyclin dependent kinases and/or
up-regulation of cyclin dependent kinase inhibitors, such as p21 or
p27 [42,43,45]. The INK4A gene locus, which encodes the cyclin
dependent kinase inhibitors p16 and p19, is inactivated in up to
80% of T-ALL cases and in all T-ALL cell lines tested [46,47].
CDK6 is the initial CDK induced during T-lymphocyte
activation/proliferation and is highly expressed in T-cell lympho-
blastic leukemias/lymphomas [48]; similarly, over-expression of
cyclin D3 is oncogenic in an array of mouse and human T-ALL
cell lines [49]. Aberrant expression of cyclin D3 and cyclin
dependent kinases during leukemic transformation underscores
their relevance as therapeutic targets for I3C/DIM.
DIM treatment effectively induced apoptosis in human T-ALL
cells in vitro and in vivo, although the apoptotic response to in vitro
treatment with DIM varied greatly among the cell lines tested.
HSB2 cells, which represent T-ALL originating from T-cells at a
very early stage of differentiation, were highly sensitive to DIM-
induced apoptosis compared to other T-ALL cell types that were
only modestly affected. This observation reinforces a general
conclusion of this report that HSB2 cells are more sensitive to the
anticancer effects of DIM in vitro. DIM treatment of CEM cells in
vitro also altered expression of mRNA transcripts belonging to the
BCL-2 superfamily or involved in TNF signaling, suggesting the
involvement of both intrinsic and extrinsic apoptotic pathways.
Others have shown that in vitro treatment with I3C or DIM inhibits
NFkB activity in human breast and prostate cancer cells
Figure 8. DIM induces apoptosis in vivo. (A) The In situ cell death detection kit (TUNEL) was applied to xenograft sections following exposure to
control diet (CTRL), 100 ppm DIM, 500 ppm I3C (I3C-L), or 2000 ppm I3C (I3C-H). Dark staining indicates apoptotic cells, and the scale bar represents
50 mm. (B) Manual and software-assisted counting was performed for xenograft sections as described in File S1 to calculate the percentage of positive
cells. ***, p,0.001 as determined by one-way ANOVA with Dunnett’s multiple comparisons post-hoc test.
doi:10.1371/journal.pone.0034975.g008
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protein expression in breast cancer cells [51]. Moreover,
expression of HRK (a BH3 domain-only BCL2 family member)
is induced in hematopoietic progenitor cells upon growth factor
removal or chemotherapeutic administration [52]. In this study,
treatment of CEM cells with 7.5 mM DIM rapidly and
continuously elevated HRK expression in vitro, which represents
a putative and novel therapeutic target of these dietary indoles.
Bioactive dietary components may be utilized as part of a
healthy lifestyle aimed at disease prevention or therapy. The
ability of I3C/DIM to target multiple pro-survival pathways in
cancer cells, while causing few adverse effects on normal cells, has
been explored in a number of cancer models with substantial
success. Collectively, our work points to the potential benefit of
exposure to these agents at early life stages for chemoprotection,
from gestation through adolescence, when leukemia is most
prevalent [26, this study]. Based on available human and animal
data [22,23], the concentrations of DIM used in this study in vitro
are likely achievable in vivo. In conclusion, our observations suggest
that DIM may be a beneficial chemotherapeutic agent or adjunct
therapy for T-ALL patients.
Supporting Information
Figure S1 Body weight gain and food consumption of
mice engrafted with human CEM cells and fed DIM or
I3C diets. Male NOD.CB17-Prkdc
scid/SzJ mice were fed diets
containing 100 ppm DIM (350 BR-DIM, X), 500 ppm I3C (n,
I3C-L), 2000 ppm I3C (#, I3C-H) or control diet (&) throughout
the xenograft study. (A) Following engraftment with CEM cells,
animals were weighed every third day to monitor the rate of
weight gain. A significant effect of experimental diet was not
observed on weight gain, as determined by a two-way repeated-
measures ANOVA (source of variation and p-value: diet
treatment, p=0.543; time, p,0.0001; interaction, p=0.053;
subjects matching, p,0.001). (B) Average food intake was assessed
daily on a per cage basis (two subjects per cage). *, p,0.05 as
determined by one-way ANOVA with Dunnett’s post-hoc multiple
comparisons test compared to control (CTRL) diet.
(TIF)
Table S1 DIM-induced changes in expression of genes
associated with apoptosis pathway in human CEM cells.
(PDF)
File S1 Supplemental methods. Additional details on
experimental methods are provided, including TUNEL analysis
of CEM cells cultured in vitro, the CEM cell xenograft study and
TUNEL analysis of human CEM cell xenografts.
(PDF)
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